Spinal Cord Stimulation for Restless Legs Syndrome

Sponsor
Marshall Holland (Other)
Overall Status
Completed
CT.gov ID
NCT03539081
Collaborator
(none)
20
1
3
45.6
0.4

Study Details

Study Description

Brief Summary

The overall goal of this proposed study is to evaluate the underlying mechanisms of neural control of blood flow in the lower extremities in humans with restless leg syndrome (RLS). At least 15% of the general public suffers from RLS and many more may go undiagnosed. This unfortunate disorder leads primarily to a disturbing sensation within the patient's lower extremities that requires movement for relief (1, 2). The central hypothesis of our study is that physiological changes in lower limb blood flow as a result of thoracolumbar epidural Spinal Cord Stimulation (SCS) lead to the relief of RLS.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Dual-energy X-ray absorptiometry Scan
  • Other: Laboratory Measurements
  • Other: Blood Flow Measurement
  • Other: Continuous Blood Pressure
  • Other: Partial pressure of oxygen
  • Other: Microneurography
  • Other: Anthropometric Measurements
  • Behavioral: John Hopkins Restless Legs Severity Scale
  • Behavioral: Continuous Blood Pressure Diary
N/A

Detailed Description

Patients age 18-85 years with (n=25) and without RLS (n=25) that have recently having undergone Spinal Cord Stimulation (SCS) implantation (thoracolumbar) for chronic pain will be recruited from the Departments of Anesthesia and Neurosurgery, University of Iowa Hospitals and Clinics. The rationale for studying both RLS patients and non-RLS patients with chronic back pain is to initially test the effectiveness of Spinal Cord Stimulation (SCS) on lower limb blood flow in the absence of symptoms of RLS. In the non-RLS patients, we could determine if SCS does in fact alter limb blood flow. We hypothesize that RLS patients have altered muscle sympathetic nerve activity (MSNA) and blood flow correlating to severity of RLS symptoms, which will then be modulated by Spinal Cord Stimulation (SCS), allowing for resolution of symptoms in RLS with MSNA-mediated improvements in leg blood flow. We also hypothesize that SCS in RLS patients will reduce 24-hour ambulatory blood pressure in parallel with reductions in MSNA.

Those deemed eligible to participate will be invited for 2 visits to the Translational Vascular Physiology Laboratory in the Clinical Research Unit (CRU) of the University of Iowa Hospitals and Clinics. Each of the 2 study visits are identical except for experimental measurements that are made at each of the five measurement time points when the Spinal Cord Stimulation (SCS) unit is either on or off as described below.

Visit 1: Experimental measurements include non-invasive "gold standard" measures of limb blood flow and arterial stiffness including femoral artery blood flow via Doppler ultrasound, calf blood flow from strain gauge venous occlusion plethysmography, and arterial stiffness via pulse wave velocity using applanation tonometry. Additionally, participants will be asked to assess the current level of leg discomfort every 10 minutes while measurements are taken by the SIT test, a validated technique for assessing restless legs symptoms where patients are asked to set and rest quietly during measurement talking, moving as little as possible (3).

Visit 2: Experimental measurements include direct measures of sympathetic nerve activity using microneurography before, during and again after administration of SCS to the patient. Additionally, participants will be asked to assess the current level of leg discomfort every 10 minutes while measurements are taken by the SIT test, a validated technique for assessing restless legs symptoms where patients are asked to set and rest quietly during measurement taking, moving as little as possible (3).

Some participates may visit the laboratory for placement of a 24-hour ambulatory blood pressure cuff.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Subjects are assigned to one of two groups based on whether they have Restless Leg Syndrome to undergo experimental measurements that are made at each of the five measurement time points.Subjects are assigned to one of two groups based on whether they have Restless Leg Syndrome to undergo experimental measurements that are made at each of the five measurement time points.
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Investigating Mechanisms of Human Spinal Cord Stimulation for Purpose of Treating Restless Leg Syndrome
Actual Study Start Date :
Jul 5, 2016
Actual Primary Completion Date :
Apr 23, 2020
Actual Study Completion Date :
Apr 23, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Subjects with RLS

Subjects with Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain. Intervention: Use of epidural spinal cord stimulation.

Diagnostic Test: Dual-energy X-ray absorptiometry Scan
Body composition analysis will be obtained by DEXA scan.
Other Names:
  • DEXA
  • Other: Laboratory Measurements
    The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).

    Other: Blood Flow Measurement
    The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.

    Other: Continuous Blood Pressure
    Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
    Other Names:
  • 24-hour Ambulatory Blood Pressure Cuff
  • Other: Partial pressure of oxygen
    Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.

    Other: Microneurography
    The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.

    Other: Anthropometric Measurements
    Height and weight will be obtained.

    Behavioral: Continuous Blood Pressure Diary
    Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.

    Other: Subjects without RLS

    Subjects without Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain. Intervention: Use of epidural spinal cord stimulation.

    Diagnostic Test: Dual-energy X-ray absorptiometry Scan
    Body composition analysis will be obtained by DEXA scan.
    Other Names:
  • DEXA
  • Other: Laboratory Measurements
    The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).

    Other: Blood Flow Measurement
    The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.

    Other: Continuous Blood Pressure
    Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
    Other Names:
  • 24-hour Ambulatory Blood Pressure Cuff
  • Other: Partial pressure of oxygen
    Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.

    Other: Microneurography
    The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.

    Other: Anthropometric Measurements
    Height and weight will be obtained.

    Behavioral: John Hopkins Restless Legs Severity Scale
    Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.

    Behavioral: Continuous Blood Pressure Diary
    Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.

    Other: Continous BP Monitoring

    This arm consists of subjects from arm "Subjects with RLS", "Subjects without RLS", and the rest of the qualifying subjects undergoing continuous blood pressure portion of the study only. Intervention: Use of epidural spinal cord stimulation.

    Other: Continuous Blood Pressure
    Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
    Other Names:
  • 24-hour Ambulatory Blood Pressure Cuff
  • Behavioral: Continuous Blood Pressure Diary
    Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.

    Outcome Measures

    Primary Outcome Measures

    1. Thoracolumbar epidural SCS will decrease MSNA [1.5 Hours]

      Response will measured by peroneal nerve microneurography to the lower limb during epidural spinal cord stimulation in patients with chronic back pain.

    2. Thoracolumbar epidural SCS will increase femoral artery blood flow [1.5 Hours]

      The response will be measured by Doppler ultrasound of the femoral artery during epidural spinal cord stimulation in patients with chronic back pain.

    Secondary Outcome Measures

    1. Thoracolumbar epidural SCS will decrease MSNA in patients with RLS. [1.5 Hours]

      Response will measured by peroneal nerve microneurography to the lower limb during epidural spinal cord stimulation.

    2. Acute thoracolumbar epidural SCS will increase femoral artery blood flow in patients with RLS. [1.5 Hours]

      This response will be measured by Doppler ultrasound of the femoral artery.

    3. Acute thoracolumbar epidural SCS will improve severity of clinical symptoms in patients with RLS. [1.5 Hours]

      Patients will report a subjective rating of 0-10 of current RLS symptoms during spinal cord stimulation.

    4. Acute thoracolumbar epidural SCS will improve oxygenation of the foot compared to the chest. [1.5 Hours]

      Transcutaneous partial pressure of oxygen will be measured on patients chest and foot.

    Other Outcome Measures

    1. Thoracolumbar epidural SCS will decrease 24-hour ambulatory blood pressure. [48 hours]

      Patients will wear continuous blood pressure monitor for 48 hours with a spinal cord simulator on and off while keeping a diary of simulator use.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Mental capacity to understand and decide to participate in the research

    • Recently have undergone or are planning to undergo SCS implantation (thoracolumbar region) for chronic pain.

    Exclusion Criteria:
    • Peripheral vascular disease

    • History of ischemic heart disease ( examples myocardial infarction, cardiac bypass surgery, coronary stent, unstable angina)

    • Heart transplantation

    • Renal Failure

    • Congestive heart failure

    • Type 1 diabetes

    • Pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Iowa Hospitals and Clinics Iowa City Iowa United States 52242

    Sponsors and Collaborators

    • Marshall Holland

    Investigators

    • Principal Investigator: Marshall Holland, MD, University of Iowa

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Marshall Holland, MD, University of Iowa
    ClinicalTrials.gov Identifier:
    NCT03539081
    Other Study ID Numbers:
    • 201605777
    First Posted:
    May 29, 2018
    Last Update Posted:
    Apr 24, 2020
    Last Verified:
    Apr 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Marshall Holland, MD, University of Iowa
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 24, 2020